Advertisement

Tumor Biology

, Volume 34, Issue 4, pp 2189–2193 | Cite as

RETRACTED ARTICLE: CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population

Research Article

Abstract

The CYP2D6 gene has been suggested to play an important role in the pathogenesis of lung cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of CYP2D6 T188C variant with lung cancer. Published literature from PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang data were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed- or random-effects model. A total of nine studies (1,516 lung cancer cases and 1,950 controls) for CYP2D6 T188C variant were included in the meta-analysis. The meta-analysis indicated that compared with CYP2D6 TT genotype, non-TT genotype (CC or CT) was significantly associated with lung cancer in the Chinese (OR = 1.61, 95 % CI = 1.38–1.87, p < 0.001), with no evidence of between-study heterogeneity (I2 = 0.0 %, p = 0.991). The sensitivity analysis indicated that the association was stable and no publication bias was detected. The present meta-analysis supported the positive association of CYP2D6 T188C variant with lung cancer in the Chinese. Further large-scale studies with the consideration for gene–gene/gene–environment interactions should be conducted to investigate the association.

Keywords

CYP2D6 Polymorphism Lung cancer Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Piskac-Collier AL, Monroy C, Lopez MS, Cortes A, Etzel CJ, Greisinger AJ, et al. Variants in folate pathway genes as modulators of genetic instability and lung cancer risk. Genes Chromosomes Cancer. 2011;50:1–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Gao Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res. 1999;444:441–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Gu Y, Zhang S, Lai B, Wang H, Zhan X. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility. Chin J Lung Cancer. 2004;7:112–7. Chinese.Google Scholar
  7. 7.
    Li WY, Lai BT, Zhan XP. The relationship between genetic polymorphism of metabolizing enzymes and the genetic susceptibility to lung cancer. Chin J Epidemiol. 2004;25:1042–5. Chinese.Google Scholar
  8. 8.
    Guo Z, Zhou Q, Zhu W, Li D, Yuan T, Wang Y, et al. A case–control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer. Chin J Lung Cancer. 2005;8:89–94. Chinese.Google Scholar
  9. 9.
    Liang GY. Studies on susceptibility genes of lung cancer in Chinese Han population and rapid detection techniques of single nucleotide polymorphisms. Doctoral Dissertation of Southeast University, 2005; 1–108. Chinese.Google Scholar
  10. 10.
    Gu YF, Zhang ZD, Zhang SC, Zheng SH, Jia HY, Gu SX. Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility. Chin Med J. 2007;87:3064–8. Chinese.Google Scholar
  11. 11.
    Yan Z, Wu YM, Wu YJ. CYP2D6*10 polymorphisms and lung cancer susceptibility. Acta Acad Med Sin. 2008;30:564–8. Chinese.Google Scholar
  12. 12.
    Zhang JJ. Single nucleotide polymorphisms of CYP2D6 gene G4268C, C188T and ERCC1 gene C8092A and their genetic susceptibility to lung cancer. Master's thesis of China Medical University, 2010; 1–37.Google Scholar
  13. 13.
    Zhou JL, Yao ZJ, Zeng ZP, Zhao XR, Xu Y, Cai XL, et al. Case–control study for the relationship of CYP1A1 and CYP2D6 polymorphisms with the genetic susceptibility to lung cancer. Acad J Guangdong Coll Pharm. 2011;27:528–31. Chinese.Google Scholar
  14. 14.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  16. 16.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMedGoogle Scholar
  17. 17.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol. 1997;51:389–93.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:3165–72.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Yan Huang
    • 1
    • 2
  • Xin Liu
    • 3
  • Xin Kuang
    • 2
  • Duanfang Liao
    • 1
    • 4
  1. 1.University of South ChinaHengyangChina
  2. 2.Department of Traditional Chinese MedicineThe first hospital affiliated to University of South ChinaHengyangChina
  3. 3.Department of AnesthesiologyThe first hospital affiliated to University of South ChinaHengyangChina
  4. 4.Hunan University of Chinese MedicineChangshaChina

Personalised recommendations